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Assessing the Impact of Psoriasis and 
the Relevance of Qualitative Research
Ray Jobling1 and Luigi Naldi2
Living with psoriasis is a lifetime experience. The lack of a cure combines with a 
peculiar public response of disinterest if not prejudice and stigmatization. Various 
factors account for changes in quality of life measures that seem independent 
from disease severity and effectiveness of treatment. Merging a qualitative and 
individual case analysis with assessment of quality of life would represent a direc-
tion for future studies.
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I am silvery, scaly. Puddles of flakes 
form wherever I rest my flesh . . . Lusty, 
though we are loathsome to love . . . 
The name of the disease, spiritually 
speaking, is Humiliation.
John Updike, 
“From the Journal of a Leper”
Psoriasis should be considered only 
in long-term perspective. Living with 
psoriasis and attempting to manage 
it can involve a lifetime experience, 
a fact not fully elucidated by exist-
ing research. Psoriasis is a distinctive 
chronic disorder in some respects. 
Generally speaking, of course, dis-
ease “chronicity” derives from failure 
or incomplete success with disease 
management (Bury, 1982; Delmar et 
al., 2005). But long-term conditions 
are not all the same. Some result from 
surviving severe, continuing compli-
cations of disorders such as cancer 
or diabetes, others from the conse-
quences of strenuous heroic treatment 
efforts such as organ transplantation or 
complex surgical procedures. These 
can by their nature grant survivors 
a measure of public understanding, 
sympathy, and recognition. Chronicity 
in psoriasis has a rather different qual-
ity. It reflects inability both to secure 
lasting day-to-day control, and also to 
prevent recurrent acute relapses. The 
drive for nearly complete clearance 
of symptoms on a long-term basis 
dominates the lives of a great many 
patients, who make valiant if imperfect 
efforts to adhere to regimens drawn up 
by their doctors. But it must be ques-
tioned whether such a task, even in 
modern dermatology, is really achiev-
able. At least up to a few years ago, the 
demanding burden of cumbersome 
treatment modalities contributed to 
disability in psoriasis (Jobling, 1992). 
For many patients these involved 
exhausting, yet unsatisfying Sisyphean 
labors, physically, psychologically, and 
socially burdensome (Jobling, 1988). 
Advances in recent years have prom-
ised more effective management at 
an acceptable risk. However, in truth, 
only preliminary data are available to 
document real progress.
The lack of a cure for psoriasis com-
bines with a distinctive psychosocial 
reaction to the disease, and to treat-
ment of the disease. It has been repeat-
edly pointed out that public response 
to skin disease is not necessarily one 
of understanding and empathy but, 
rather, tends to be at best a lack of 
interest in, and disregard for, its impli-
cations for those who have it — if not 
prejudice and stigmatizing negative 
judgments (Jobling, 2001). The origins 
of such a response are to be found 
deeply rooted in history and culture. 
Negative connotations and moral 
evaluation attach to skin manifesta-
tions. A spotted or scarred surface has 
been associated at least since medi-
eval times in Western countries with 
the idea of impurity. Demons, such as 
Harlequin, usually have spotted skin 
or clothes (Pastoureau, 1991). For cen-
turies, in many different cultures, skin 
diseases have been associated with 
disgrace and danger. A notable aspect 
of this is the connotation of dirtiness 
attaching to them, bound up with 
fears of infection or contagion but not 
by any means wholly understandable 
and explicable in these terms. There is 
no doubt that, however unjustifiable 
it may be in rational, factual terms, 
those with psoriasis do feel culpable, 
ashamed and guilty at committing and 
giving offense (Jobling, 2001).
It is not surprising that quality-of-
life measures are affected in psoriasis 
to a degree comparable with that seen 
in clinically severe conditions such 
as diabetes or cancer (Kimball et al., 
2005; Russo et al., 2004). Importantly, 
in a number of studies, subjective 
experience of psoriasis was a more 
powerful determinant of quality of life 
than the degree of objective severity, 
indicated by the area of affected sites, 
for example (Russo et al., 2004). But 
do we really have measures that ena-
ble us to encapsulate, summarize, and 
effectively convey the full life impact 
of the experience of the disease, and 
its impact over a very long duration? 
Existing quality-of-life measures main-
ly rely on limited questions concerning 
reported daily-life experience during 
the day, week, or month preceding the 
interview or assessment. How much 
of the complex interrelation among 
disease severity, individual adapta-
tion, and public response is captured 
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| Over time, patients have recalibrated their self-assessment of disability.
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by such instruments? There are few 
studies devoted to exploration, using 
in-depth structured interviews and 
qualitative analysis, of possible cor-
relations between quality-of-life indi-
cators and patient interpretation and 
summarization of disease experience 
(Errser et al., 2002; Jobling, 2005).
The paper by Unaeze et al. (2006, 
this issue) has many merits.
First, it demonstrates the useful-
ness of securing a long-term view 
on the impact of psoriasis, achieved 
by the adoption of a cohort study 
design. We are indebted to the PUVA 
Follow-Up Study for enhancing our 
understanding of psoriasis in many 
different areas, from the safety profile 
of UV light treatment (Stern and Laird, 
1994) to prognostic factors (Melski 
et al., 1983) to quality-of-life issues. 
Unfortunately, no other similar long-
term study has been conducted with 
regard to any other new treatment 
modality, including cyclosporin and, 
notably, the new biological agents. 
It is a significant gap and deficiency, 
which the dermatological research 
community needs to address.
The paper by Unaeze et al. (2006) 
also highlights the complexity of 
factors accounting for changes in qual-
ity-of-life measures when a long-term 
perspective on the disease is taken. It 
identifies self-reported general health 
and age as confounding factors to 
be considered in the comparison of 
quality-of-life changes among groups 
over time. By pointing to changes that 
seem independent of physical disease 
severity and the effectiveness of treat-
ment in that regard, the paper under-
lines the need for examination of 
chronic diseases such as psoriasis in 
their “natural” setting or environment 
rather than in the artificial conditions 
of the clinic; and for consideration of 
medical care in its social context to 
obtain a more holistic and balanced 
view of the many factors that influ-
ence long-term outcome, especially 
patient-assessed benefit.
Unfortunately, Unaeze et al. (2006) 
did not assess correlates of changes in 
terms of coping strategies and accom-
modation to the disease. How far the 
shifts in the adopted measures trans-
late into a sense of subjectively better 
and genuinely more satisfactory life 
experience is also hard to determine 
on the basis of the data at hand. The 
degree to which a person has inter-
nalized negative social stereotypes, 
the level of self-esteem, the anticipa-
tory threat and fear of social rejec-
tion, the availability of social support, 
the importance attached to appear-
ance, and possible underlying reactive 
depression may all be related to differ-
ent degrees of improvement in quality-
of-life measures. This study was based 
on data collected from a relatively 
older age group, and only two points 
in time were considered. Changes 
over time may vary in different age 
groups, and 10-year variations in peo-
ple aged 30 years may be remarkably 
different from those in people aged 50 
or 60 years. It is perhaps quite under-
standable that feelings of unattrac-
tiveness, embarrassment, and shame 
might be less a problem in older age 
groups, although we do not have much 
hard evidence on the matter, certainly 
not in comparative perspective. It is 
an important finding that, over time, 
patients have recalibrated their self-
assessment of disability, reporting high-
er life quality than observers (including 
their doctors) would have anticipated. 
Withdrawal from, or at least reduced 
involvement in, treatment, and chang-
es in treatment that limit its objectives, 
can perhaps relieve the strain and the 
burden. Treatment indeed might in this 
sense be only a marginal factor in the 
enhancement of life quality, which is 
associated with such “natural” accom-
modation to the disease (assisted, 
as Unaeze et al. (2006) suggest, by 
social support). Overzealous treatment 
directed toward goals perhaps unde-
sired and unsought by patients could 
by contrast contribute to continuing 
damage to psychosocial functioning. 
There are of course few, if any, studies 
making explicit cross-cultural compar-
isons in all of this. Moreover, it may be 
that the trend toward improvement in 
well-being is not a straight line, with 
changes distributed uniformly over 
time. It would be of interest to assess 
whether a similar trend toward such 
improvement is documented for other 
skin disorders with potential to affect 
body image.
In primary research, more imagi-
native and effective instruments are 
needed, and research strategies should 
be developed that take account of 
the possibly distinctive peculiarities 
of dermatology as compared with 
other disciplines. Qualitative research 
should not be neglected. It is the first 
key to determining, unraveling, and 
understanding intercultural (cross- and 
subcultural) conceptions, and relat-
ed variations in body image, coping 
strategies, and ways in which health 
needs prompted by skin diseases 
are expressed and perceived in differ-
ent situations.
Merging qualitative and individual 
case analysis with quantitative assess-
ment of quality of life would represent 
a valuable direction for future stud-
ies of disease impact and treatment 
outcome in psoriasis. More carefully 
controlled evaluation of non-pharma-
cological interventions such as edu-
cation, cognitive intervention, and 
psychological support as adjuncts to 
conventional treatment would also be 
worthwhile. More than 25 years after 
Engel introduced the biopsychosocial 
model into medicine (Engel, 1977), 
psoriasis remains a common, disfigur-
ing, and potentially disabling disease. 
Our understanding of the implications 
of continuous treatment for the lives of 
patients is limited. Clinicians who care 
for patients with psoriasis need to be 
mindful of its less visible challenge to 
well-being, including psychological 
distress and the risk of reactive depres-
sion. Dermatologists should, too, 
consider ways of more effectively and 
sensitively developing social, commu-
nity, and public-health perspectives in 
their professional practice, addressing 
damaging cultural conceptions and 
social arrangements, besides managing 
individual patients. In that process there 
is naturally a need to be alert to the 
risks of unintended consequences in 
disease-awareness campaigning.
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Pseudoxanthoma Elasticum: a 
Metabolic Disease?
Qiujie Jiang1 and Jouni Uitto1
Pseudoxanthoma elasticum (PXE), a pleiotropic multisystem disorder affect-
ing the skin, eyes, and cardiovascular system, is caused by mutations in the 
ABCC6/MRP6 expressed primarily in the liver. A question has arisen regarding 
the pathomechanism of PXE, particularly the "metabolic" versus the "PXE cell" 
hypotheses. Le Saux et al. have now provided partial support for the notion that 
PXE is primarily a metabolic disorder.
Journal of Investigative Dermatology (2006) 126, 1440–1441. doi:10.1038/sj.jid.5700267
Pseudoxanthoma elasticum (PXE; 
OMIM 264800, 177850) is an auto-
somal recessive disease with pro-
tean manifestations in the skin, the 
eyes, and the cardiovascular system 
(Neldner, 1988; Ringpfeil et al., 2006). 
Histopathologic examination of the 
cutaneous lesions reveals accumula-
tion of pleiomorphic elastotic material 
that demonstrates progressive calcifi-
cation, and similar pathologic chang-
es have been demonstrated in other 
affected tissues. On the basis of these 
and related observations, PXE was, 
early on, thought to be a heritable con-
nective tissue disorder with abnormali-
ties in the elastic fibers. Specifically, 
this condition was thought to reflect 
mutations in the genes encoding the 
components of the elastic fibers, and 
PXE was suggested to be the prototype 
of heritable connective tissue disor-
ders. However, the advent of clon-
ing of the genes encoding elastin and 
the associated microfibrillar proteins 
allowed performance of genetic link-
age analyses of families with PXE, 
which systematically excluded the 
majority of known extracellular matrix 
genes. Subsequently, positional clon-
ing attempts mapped the PXE locus 
on chromosomal region 16p13.1, and 
direct sequencing of the genes within 
the critical interval allowed identifica-
tion of mutations in the ABCC6 gene, 
which encodes multidrug resistance-
associated protein 6 (MRP6) (Chassaing 
et al., 2005; Miksch et al., 2005).
ABCC6 has been shown to be 
expressed primarily in the liver and to 
a lesser extent in the proximal tubules 
of the kidneys, and only at very low 
levels, if at all, in tissues affected in 
PXE, that is, the skin, eyes, and car-
diovascular system. This observation 
allowed us to hypothesize early on 
that PXE may be a metabolic disorder 
at the genome–environment interface 
(Uitto et al., 2001). An alternative 
hypothesis, advanced primarily on the 
basis of work on fibroblast cultures 
established from the skin of patients 
with PXE, which display abnormalities 
in cell–cell and cell–matrix adhesion 
properties, in the proliferative capacity 
of the cells, and in the rate of synthesis 
of connective tissue components such 
as elastin, collagen, and proteogly-
cans, postulates that PXE results from a 
primary connective tissue defect based 
on abnormalities in the resident cells 
in affected tissues, including fibro-
blasts in the skin and smooth muscle 
cells in vascular connective tissues 
(Pasquali-Ronchetti et al., 2006). The 
question of the precise nature of the 
abnormalities — generalized and met-
abolic versus localized and cell spe-
cific — clearly has implications for the 
understanding of the pathomechanisms 
leading from mutations to the clinical 
phenotype. Consequently, decipher-
ing the mechanistic details of molecu-
lar pathology allows development of 
interventional strategies directed at the 
specific abnormalities. For example, 
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